The Care Pathway for an Adult Patient with Type 2 Diabetes Suffering from Chronic Kidney Disease (CKD) in France

Author(s)

Penfornis A1, Koerber C2, Billaut I3, Miadi H4
1Centre Hospitalier Sud Francilien, Corbeille Essone, France, 2Bayer Healthcare SAS, Lille, France, 3Bayer Healthcare SAS, LOOS, 59, France, 4Bayer Healthcare SAS, Lille, 59, France

OBJECTIVES

Considered as a major public health issue, chronic kidney disease (CKD) is an insidious and deleterious complication of diabetes, which is managed late in its evolution. In order to improve the management of type 2 diabetic patients (T2D) with CKD, knowledge of the care pathway in France of these patients and the qualification of the key issues and needs of each actor involved are essential elements, and yet still imprecise.

The objective of this analysis is to improve knowledge of the current care pathway for type 2 diabetic patients with chronic renal disease and to best qualify the key issues and needs of the various actors identified in this care pathway

METHODS

In order to have the most complete vision possible of the ecosystem in which the adult patient with type 2 diabetes and chronic kidney disease evolves, a review of the literature, supplemented by interviews with clinical experts (diabetologists, nephrologists, general practitioners, pharmacists, advanced practice nurses) were conducted as part of this research.

RESULTS

:
The research carried out led to divide the care pathway of the T2D patient with CKD into five stages, in which different breaking points were identified. This care pathway is currently heterogeneous and unsuitable for the diabetic patient. Thus, the care teams and the French health authorities must define a comprehensive care pathway and strengthen support for these patients, in order to slow the progression of chronic kidney disease and reduce the use of renal replacement therapy. The experiments implemented today demonstrate the interest of institutions and health professionals in the care management of T2D patients with CKD and partially meet the needs and challenges identified.

CONCLUSIONS

:
No experiments specific to care management of T2D patient developing CKD have been identified. Further efforts are now necessary to significantly improve the care pathway of these patients.

Conference/Value in Health Info

2020-11, ISPOR Europe 2020, Milan, Italy

Value in Health, Volume 23, Issue S2 (December 2020)

Code

PUK23

Topic

Epidemiology & Public Health, Health Service Delivery & Process of Care

Topic Subcategory

Disease Management, Public Health, Telemedicine

Disease

Diabetes/Endocrine/Metabolic Disorders, Urinary/Kidney Disorders

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×